Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01127750 | Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients | PHASE3 | COMPLETED | 2,417 | — | — | May 1, 2010 | Oct 1, 2011 | Feb 23, 2017 | 289 | Australia, Austria +21 |
| Arm | Type | Description |
|---|---|---|
| FTY720 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FTY720 | DRUG | - |
Inclusion Criteria: * 18-65 years of age, must have relapsing MS Exclusion Criteria: * Patients with a type of MS that is not relapsing * Patients with history of chronic immune disease * Patients with a history of certain cancers * Diabetic patients with certain eye disorders * Patients who are ...